脂肪与肌肉质量与前��腺癌男性总生存期的关联:系统综述与荟萃分析
结果显示总脂肪和内脏脂肪与总生存期无显著关联,而较高的皮下脂肪与更高生存率相关,低肌肉质量与局部及晚期疾病更高的死亡风险相关。
要点
- 总脂肪与内脏脂肪与前列腺癌患者总生存期无显著关联。
- 较高皮下脂肪水平与更高生存率相关(HR 0.68)。
- 低肌肉质量与局部和晚期前列腺癌更高死亡风险相关。
核心结论
- 总脂肪应谨慎解读其与生存的关联,高肌肉质量和皮下脂肪及低内脏/皮下脂肪比值与前列腺癌男性总生存期相关。
主要发现
- 总脂肪与总生存期无显著关联(HR 0.98,95% CI:0.75-1.28,p=0.888)。
- 内脏脂肪与总生存期无显著关联(HR 1.03,95% CI:0.74-1.43,p=0.873)。
- 较高皮下脂肪水平与更高生存率相关(HR 0.68,95% CI:0.54-0.84,p=0.001)。
- 局部疾病低肌肉质量者死亡风险更高(HR 1.91,95% CI:1.40-2.62,p<0.001)。
- 晚期疾病低肌肉质量者死亡风险更高(HR 1.43,95% CI:1.07-1.92,p=0.020)。
临床怎么用
- 在前列腺癌患者评估中可关注肌肉质量,低肌肉质量提示局部和晚期疾病死亡风险增高。
- 皮下脂肪较高与生存改善相关,但总脂肪和内脏脂肪的生存关联不显著,解读体成分指标需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To systematically review and analyse the associations between fat and muscle mass measures with overall survival in men with prostate cancer. METHODS: A systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases from inception to December 2020, while abstracts from the American Society of Clinical Oncology (ASCO), Clinical Oncology Society of Australia (COSA), and the American College of Sports Medicine (ACSM) conferences were searched from 2014 to 2020. Eligible articles examined the association of body composition measures, such as fat mass (e.g., fat mass, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and VAT/SAT) and muscle mass measures, with overall survival in prostate cancer patients at any treatment stage. The primary endpoint was overall survival. Random-effect meta-analysis was conducted for studies reporting multivariable or univariable analysis assessing the associations of fat mass measures (i.e., fat mass, VAT, SAT, VAT/SAT) and muscle mass measures with overall survival. RESULTS: Sixteen cohort studies that comprised 4807 men with prostate cancer were included. Total adiposity (hazard ratio (HR) 0.98, 95% CI: 0.75-1.28, p = 0.888) and VAT (HR 1.03, 95% CI: 0.74-1.43, p = 0.873) were not significantly associated with overall survival, while higher subcutaneous adipose tissue levels were associated with higher survival (HR 0.68, 95% CI: 0.54-0.84, p = 0.001). Greater mortality risk was found in patients with localised (HR 1.91, 95% CI: 1.40-2.62, p < 0.001) and advanced disease (HR 1.43, 95% CI: 1.07-1.92, p = 0.020) presenting with low levels of muscle mass compared to those presenting with high levels. DISCUSSION: These results indicate that although overall adiposity should be cautiously interpreted in regards to survival, high muscle mass and SAT, and low VAT/SAT ratio values are associated with overall survival in men with prostate cancer.
引用
- Lopez P, Newton RU, Taaffe DR, et al. Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 34420038. doi:10.1038/s41391-021-00442-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。